Company intelligence / Profile preview

Jossa Arznei

Munich, Bavaria, Germany

Ownership: Private
Development stage: Other

Overview

Jossa Arznei GmbH is a Munich-based investment and holding company that plays a strategic role in the German life sciences and biotechnology sector. It serves as a key vehicle for the Strüngmann family, the founders of Hexal and early backers of BioNTech, to manage and grow their pharmaceutical interests. The company provides long-term capital and strategic guidance to a portfolio that includes established pharmaceutical firms and innovative biotech companies such as Glycotope, Klinge Pharma, and Arevipharma. By focusing on both drug development and specialized manufacturing, Jossa Arznei acts as a vital bridge between financial investment and clinical innovation within the European healthcare ecosystem.

Industry: Investors

Partnerships

ATHOS KGSanto Holding

Beyond the preview

Go deeper on Jossa Arznei.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jossa Arznei.

Explore the full profile